Please assess the completion status of the following clinical trial:

Trial Title: Spiolto® Respimat® (Tiotropium/Olodaterol) Versus Triple Combination Therapy in Everyday Clinical Treatment Practice for Chronic Obstructive Pulmonary Disease (EVELUT®)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients can be included if all of the following criteria are met:~* Diagnosis of COPD~* Symptomatic (with regard to dyspnea (mMRC Dyspnea score ≥1) AND with regard to symptoms (CAT Score ≥10) at the same time)~* Patients on LABA/ICS maintenance therapy who are switched to Spiolto® Respimat® in the new reusable inhaler or a free/fixed triple combination of LABA + LAMA + ICS at Visit 1 at the discretion of the treating physician.~* Adults who are contractually capable and mentally able to understand and follow the instructions of the study personnel~* Male or female~* Patients aged ≥40 years of age~* Written informed consent prior to study participation~* The patient is willing and able to follow the procedures outlined in the protocol~Exclusion Criteria:~* Patients with contraindications acc. to SmPC~* Patients not on LABA/ICS maintenance treatment at visit 1, e.g., mono or dual bronchodilation only, ICS only, or a triple combination of LAMA + LABA + ICS (either as a fixed combination product or as separate components)~* Lack of informed consent~* Pregnant and/or lactating females~* Acute exacerbation of COPD (within 4 weeks prior to Visit 1)~* Frequently exacerbating patients, i. e. patients with ≥2 moderate exacerbations within the last 12 months or ≥1 exacerbation leading to hospitalization within the last 12 months~* Acute respiratory failure (pH \<7,35 and/ or respiratory rate \>30/min within 3 months prior to Visit 1)~* History or current diagnosis of asthma~* History or current diagnosis of asthma-COPD overlap~* History or current diagnosis of allergic rhinitis within the last 5 years~* History or current diagnosis of lung cancer within the last 5 years~* Participation in a parallel interventional clinical trial~* mild exacerbation: additional use of short-acting bronchodilators and treated by the patient without consulting a physician~* moderate exacerbation: treatment includes medical prescription of a systemic corticosteroid and/or antibiotic~* severe exacerbation: exacerbation leading to hospitalization

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Spiolto® Respimat® (Type: None): Chronic Obstructive Pulmonary Disease (COPD) patients who were symptomatic (dyspneic) despite Long-acting beta2 adrenoceptor agonist/Inhalative Corticosteroids (LABA/ICS) maintenance treatment were switched to Spiolto® Respimat® inhaler by their attending physician in an real-world setting.
- Triple-Therapy (LAMA/LABA/ICS) (Type: None): Chronic Obstructive Pulmonary Disease (COPD) patients who were symptomatic (dyspneic) despite Long-acting beta2 adrenoceptor agonist/Inhalative Corticosteroids (LABA/ICS) maintenance treatment were switched to any triple therapy Long-acting muscarinic antagonist + Long-acting beta2 adrenoceptor agonist + Inhalative Corticosteroids (LAMA + LABA + ICS) by their attending physician in an real-world setting.

Based on this trial design, predict the completion outcome and termination type (if applicable).